JP2008543862A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543862A5
JP2008543862A5 JP2008517090A JP2008517090A JP2008543862A5 JP 2008543862 A5 JP2008543862 A5 JP 2008543862A5 JP 2008517090 A JP2008517090 A JP 2008517090A JP 2008517090 A JP2008517090 A JP 2008517090A JP 2008543862 A5 JP2008543862 A5 JP 2008543862A5
Authority
JP
Japan
Prior art keywords
less
chloride
composition
administration
azelnidipine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023243 external-priority patent/WO2006138421A2/en
Publication of JP2008543862A publication Critical patent/JP2008543862A/ja
Publication of JP2008543862A5 publication Critical patent/JP2008543862A5/ja
Pending legal-status Critical Current

Links

JP2008517090A 2005-06-15 2006-06-14 ナノ粒子アゼルニジピン製剤 Pending JP2008543862A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69071605P 2005-06-15 2005-06-15
PCT/US2006/023243 WO2006138421A2 (en) 2005-06-15 2006-06-14 Nanoparticulate azelnidipine formulations

Publications (2)

Publication Number Publication Date
JP2008543862A JP2008543862A (ja) 2008-12-04
JP2008543862A5 true JP2008543862A5 (cg-RX-API-DMAC7.html) 2009-07-16

Family

ID=37571129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517090A Pending JP2008543862A (ja) 2005-06-15 2006-06-14 ナノ粒子アゼルニジピン製剤

Country Status (5)

Country Link
US (1) US20100221327A1 (cg-RX-API-DMAC7.html)
EP (1) EP1931340A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008543862A (cg-RX-API-DMAC7.html)
CA (1) CA2612384A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006138421A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI414310B (zh) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd 溶出性改善之醫藥品組成物
CN101969934B (zh) * 2007-12-13 2012-11-21 国立大学法人九州大学 包含药物的纳米颗粒
CN101486705B (zh) * 2009-03-05 2012-08-08 青岛黄海制药有限责任公司 一种阿折地平α晶型的制备方法
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
US20140031557A1 (en) * 2011-04-18 2014-01-30 Hefeibeinie Medical Technology Company, Ltd. Method for purification of calcium channel blockers of dihydorpyridine type and preparation of nanoparticles thereof
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
EP2804606B1 (en) 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
BR112014028610A2 (pt) * 2012-05-17 2017-06-27 Contract Pharmaceuticals Ltd formulações de vesícula não iônica de bloqueadores de canal de cálcio

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4772596A (en) * 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU2317592A (en) * 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
EP1128858A1 (en) * 1998-11-13 2001-09-05 Elan Pharma International Limited Drug delivery systems and methods
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CA2393195C (en) * 1999-06-01 2007-02-20 Elan Pharma International Limited Small-scale mill and method thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
BR0109991A (pt) * 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
ATE453454T1 (de) * 2000-04-26 2010-01-15 Elan Pharma Int Ltd Vorrichtung zur sanitären nassvermahlung
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1392441B1 (en) * 2001-06-05 2008-07-23 Elan Pharma International Limited System and method for milling materials
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
PT1471887E (pt) * 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1490025B1 (en) * 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
ATE419835T1 (de) * 2002-05-06 2009-01-15 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
WO2005044234A2 (en) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery

Similar Documents

Publication Publication Date Title
JP2009528349A5 (cg-RX-API-DMAC7.html)
JP2010013462A5 (cg-RX-API-DMAC7.html)
JP2011042670A5 (cg-RX-API-DMAC7.html)
JP2005511507A5 (cg-RX-API-DMAC7.html)
JP2005508939A5 (cg-RX-API-DMAC7.html)
CA2463495A1 (en) Compositions having a combination of immediate release and controlled release characteristics
US20070148100A1 (en) Nanoparticulate aripiprazole formulations
CA2498207A1 (en) Gel-stabilized nanoparticulate active agent compositions
JP2009541360A (ja) ナノ粒子状メロキシカムおよび制御放出ヒドロコドンを含む組成物
JP2005536512A5 (cg-RX-API-DMAC7.html)
CN101237868A (zh) 纳米粒氯吡格雷和阿司匹林组合制剂
KR20090015994A (ko) 나노입자형 포사코나졸 제제
JP2005530712A5 (cg-RX-API-DMAC7.html)
JP2004528267A (ja) 選択的シクロオキシゲナーゼ−２阻害性薬物の眼処方
JP2005531606A5 (cg-RX-API-DMAC7.html)
JP2005531605A5 (cg-RX-API-DMAC7.html)
JP2005526095A5 (cg-RX-API-DMAC7.html)
EP2230906A1 (en) Nanoparticulate anidulafungin compositions and methods for making the same
CA2523035A1 (en) Sterilization of dispersions of nanoparticulate active agents with gamma radiation
JP2010248220A5 (cg-RX-API-DMAC7.html)
JP2021181447A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
CN101262860A (zh) 纳米微粒对乙酰氨基酚制剂
JP2005532352A5 (cg-RX-API-DMAC7.html)
CA2488499A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
KR20110007095A (ko) 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법